共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
3.
世间万物,均从生到死,这是自然的法则。如落叶缤纷绚丽,回应着母亲的召唤,义无反顾地投向泥土的怀抱,多姿多彩地铺满大地,奇异地呈现出犹如晚霞般的灿烂辉煌。当我每每看到那些坦荡执着回归大地的落叶,我就感触万分,深深怀念着我的父亲母亲。 相似文献
5.
6.
8.
回想仿佛是很久以前的事,2002年的春天,36岁的我于茫然无知中罹患了乳腺癌,因为没有更好的选择,我只能将拯救生命的任务全部交给医生。 相似文献
9.
这是最近我与一位老同学(A)的对话,话题是:对他罹患胃癌的妻子,告诉不告诉关于癌症发展的实情。考虑这是一个社会上普遍关心的问题,我(B)将这个谈话的梗概记录下来,供关心这个问题的读者参考。 相似文献
10.
Xiaomei Li Duanqi Liu 《中德临床肿瘤学杂志》2007,6(3):P293-P295
Objective: To evaluate the analgesic efficacy as well as adverse effects of OxyContin for the treatment of moderate to severe cancer pain. Methods: OxyContin was administered at an initial dose of 10 mg every 12 h and titrated upwards according to the extent of pain relief. The analgesic effect, Karnofsky performance status (KPS) scale as well as adverse effects were investigated. Results: The mean onset time and duration of analgesic effect was 41 min and 12.6 h, respectively, with the daily average dose of 69.03 mg. Among all the 31 patients who had suffered moderate to severe pain, slight pain relief was achieved in one patient (3.23 %). Moderate, obvious and complete pain relief were achieved in 4 (12.90 %), 20 (64.52 %) and 6 (19.53%), respectively. KPS was elevated in 19 (61.29%) and stable in 9 (29.03%) patients after administration of OxyContin. 3 (9.68%) patients were died of disease deterioration. Main adverse effect was constipation in 10 cases (32.26%). Conclusion: OxyContin was effective in the treatment of moderate to severe cancer pain, with rapid onset, good analgesic performance, mild adverse effect and safety profile. 相似文献
11.
WHO发布1995年世界主要死因疾病的统计中指出,各种癌症构成第2位最重要的死因。疼痛是癌症患者主要症状之一,尤其是晚期癌症患者,疼痛发生率在70%以上,所以如何使癌症患者的疼痛得到缓解、减轻痛苦,提高其生存质量,显得十分必要。1994年6月至1996年12月,应用不同化疗方案治疗癌痛患者73例,现对连续应用2个疗程以上的病例报告如下: 相似文献
12.
Shejuan An Jianquan Zhu Zhihong Chen Guochun Zhang Zhen Wang Yilong Wu 《中德临床肿瘤学杂志》2008,7(12):677-681
Objective: To investigate whether laminin 5 (LN5) might be a predictor in lung cancer patient treated with gefitinib and estimate the underlying mechanisms. Methods: LN5 and epidermal growth factor receptor (EGFR) mRNA expression level were detected in the tumor tissues of lung cancer patients who underwent surgery resection prior to gefitinib treatment. EGFR exon 19 and 21 mutation status was also detected in these specimens. The association between LN5, EGFR mRNA expression level, EGFR mutation and gefitinib treatment response were evaluated. In vitro study were carried by adding exog- enous LN5 and gefitinib to A549 lung cancer cell line, and Western-blotting was performed to investigate the phosphorylation level of EGFR,Ak, and Erk. Results: The disease control rate according to LN5 mRNA level was 52.9% for the below cut- point group, and 17.6% for the above cut-point (P = 0.009). The in vitro study showed that exogenous LN5 can neutralize the inhibition of phosphor-Akt by gefitinib. Conclusion: Patients with lower LN5 mRNA level would likely benefit from gefitinib. In vitro study indicated that the inhibition of Akt induced by gefitinib might be reversed by LN5. These results provide important insights into the molecular mechanisms underlying sensitivity to gefitinib in lung cancer patients. 相似文献
13.
测定血清清唾液酸用来诊断恶性肿瘤的文献较多。但其应用范围和价值并未完全一致。我们对已确诊并住院接受放疗、化疗的99例患者进行了血清唾液酸测定,结果报告如下。 相似文献
14.
15.
17.
18.
重组人红细胞生成素改善肿瘤患者放化疗相关性贫血临床观察 总被引:1,自引:0,他引:1
贫血是癌症患者常见的并发症,约50%的肿瘤患者发生贫血,晚期及接受放化疗患者因骨髓造血系统进一步抑制,贫血发生率高达90%,严重影响患者对放化疗的耐受性及生活质量。本研究应用重组人红细胞生成素(rHuEPO)治疗放化疗相关性贫血取得较好疗效。 相似文献
19.